GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spark Therapeutics Inc (NAS:ONCE) » Definitions » Earnings per Share (Diluted)

Spark Therapeutics (Spark Therapeutics) Earnings per Share (Diluted) : $-6.56 (TTM As of Sep. 2019)


View and export this data going back to 2015. Start your Free Trial

What is Spark Therapeutics Earnings per Share (Diluted)?

Spark Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2019 was $-1.72. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-6.56.

Spark Therapeutics's EPS (Basic) for the three months ended in Sep. 2019 was $-1.72. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2019 was $-6.56.

Spark Therapeutics's EPS without NRI for the three months ended in Sep. 2019 was $-1.72. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2019 was $-6.56.


Spark Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Spark Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spark Therapeutics Earnings per Share (Diluted) Chart

Spark Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Earnings per Share (Diluted)
Get a 7-Day Free Trial -1.14 -2.10 -4.29 -7.63 -2.11

Spark Therapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.26 -1.75 -1.43 -1.66 -1.72

Competitive Comparison of Spark Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Spark Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spark Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spark Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Spark Therapeutics's PE Ratio falls into.



Spark Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Spark Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2018 is calculated as

Diluted Earnings Per Share (A: Dec. 2018 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-78.822-0)/37.367
=-2.11

Spark Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2019 is calculated as

Diluted Earnings Per Share (Q: Sep. 2019 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-66.602-0)/38.748
=-1.72

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Spark Therapeutics  (NAS:ONCE) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Spark Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Spark Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Spark Therapeutics (Spark Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3737 Market Street, Suite 1300, Philadelphia, PA, USA, 19104
Spark Therapeutics Inc is a biotechnology company with a focus on gene therapy and orphan disease treatment. The company has one business segment, Pharmaceuticals, which is principally engaged in utilizing gene therapy to develop products to aid patients suffering from debilitating diseases. Spark has a pipeline with products that target choroideremia, genetic blinding conditions or inherited retinal disease, and a product targeting hematologic disorders. The company earns the vast majority of its revenue in the United States.
Executives
Elliot Sigal director
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Stephen W Webster officer: CHIEF FINANCIAL OFFICER C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel Faga officer: Chief Business Officer 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Lota S. Zoth director, officer: CHIEF SCIENTIFIC OFFICER 334 CR 692, BUFFALO GAP TX 79508
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Robert J Perez director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER ST., WALTHAM MA 02451
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Roche Holding Ltd 10 percent owner ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Katherine A High director, officer: See Remarks 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John Furey officer: Chief Operating Officer 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Vivaldi Coelho Rogerio officer: Chief Commercial Officer 225 SECOND AVENUE, WALTHAM MA 02451
Srinivas Akkaraju 10 percent owner 565 EVERETT AVENUE, PALO ALTO CA 94301
Sofinnova Venture Partners Viii, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025

Spark Therapeutics (Spark Therapeutics) Headlines

From GuruFocus